Skip to main content

Table 4 Distribution of AS on all modalities

From: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

AS WBMRI CT FDG-PET/CT BS WBMRI & CT WBMRI & FDG-PET/CT WBMRI & BS
Bone only 16 0 0 1 1 0 1
Bone and viscera/soft tissues 4 0 0 N/A 0 0 N/A
Viscera/soft tissues only 24 Liver
17
Lymph nodes
1
Lungs
1
N/A 0 Retroperitoneal
1
N/A
Lymph nodes
3
Peritoneal
2
Liver and peritoneal
2